Adams, D. Et Al. 2021. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. LANCET NEUROLOGY , vol.20, no.1 , 49-59.

Adams, D., Polydefkis, M., González-Duarte, ., Wixner, ., Patisiran, G. O. S. G., & Altınkurt, E., (2021). Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. LANCET NEUROLOGY , vol.20, no.1, 49-59.

Adams, David Et Al. "Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study," LANCET NEUROLOGY , vol.20, no.1, 49-59, 2021

Adams, David Et Al. "Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study." LANCET NEUROLOGY , vol.20, no.1, pp.49-59, 2021

Adams, D. Et Al. (2021) . "Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study." LANCET NEUROLOGY , vol.20, no.1, pp.49-59.

@article{article, author={David Adams Et Al. }, title={Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study}, journal={LANCET NEUROLOGY}, year=2021, pages={49-59} }